Disease Progression
Showing 9951 - 9975 of >10,000
Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma Trial in Hangzhou (Irinotecan
Not yet recruiting
- Advanced Biliary Tract Cancer
- +3 more
- Irinotecan Liposome Injection
- +3 more
-
Hangzhou, Zhejiang, ChinaCancer Hospital of the University of Chinese Academy of Sciences
Sep 16, 2021
Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment
Recruiting
- Liver Fibroses
- +4 more
- Observation only
-
Ansan, Korea, Republic of
- +25 more
Oct 10, 2021
Advanced Hepatocellular Carcinoma Trial in Guangzhou (Bifidobacterium Bifidum Oral Product)
Recruiting
- Advanced Hepatocellular Carcinoma
- Bifidobacterium Bifidum Oral Product
-
Guangzhou, Guangdong, ChinaThe Third Affiliated Hospital of Sun Yat-Sen University
Nov 16, 2022
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
Recruiting
- Sarcoma
- Preoperative RT
- +3 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Oct 11, 2021
Optic Pathway Glioma Trial in Rome (CHF6467, Placebo)
Not yet recruiting
- Optic Pathway Glioma
- CHF6467
- Placebo
-
Rome, ItalyCatholic University, Policlinico A. Gemelli (Hospital)
Feb 17, 2023
Squamous Cell Carcinoma of the Head and Neck Trial in United States (SNS-301, Pembrolizumab)
Terminated
- Squamous Cell Carcinoma of the Head and Neck
-
San Francisco, California
- +9 more
Dec 6, 2022
Metastatic Melanoma Trial in Lancaster, Philadelphia (Hypofractionated Radiation Therapy (HFRT), Nivolumab, Ipilimumab)
Recruiting
- Metastatic Melanoma
- Hypofractionated Radiation Therapy (HFRT)
- +2 more
-
Lancaster, Pennsylvania
- +1 more
Mar 30, 2022
Lung Diseases, Interstitial Trial in Tampa (Actigraph CP Insight Watch)
Not yet recruiting
- Lung Diseases, Interstitial
- Actigraph CP Insight Watch
-
Tampa, FloridaUniversity of South Florida/ Tampa General Hospital
May 10, 2023
Chronic Graft-versus-host-disease Trial in Goyang-si, Incheon, Seoul (SCM-CGH, Placebo)
Recruiting
- Chronic Graft-versus-host-disease
- SCM-CGH
- Placebo
-
Goyang-si, Gyeonggi-do, Korea, Republic of
- +6 more
Sep 26, 2021
High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma Trial in Worldwide (Dinutuximab, Eflornithine
Recruiting
- High Risk Neuroblastoma
- +2 more
- Dinutuximab
- +4 more
-
Birmingham, Alabama
- +141 more
Dec 28, 2022
Patient With Anterior Myocardial Infarction Trial in Sohag (-group of patients(75 patients) will receive low dose rivaroxaban
Not yet recruiting
- Patient With Anterior Myocardial Infarction
- -group of patients(75 patients) will receive low dose rivaroxaban myocardial infarction plus (acetylsalicylic acid 75 mg and clopidogrel 75 mg
- (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally only)
-
Sohag, EgyptSohag University Hospital
Feb 16, 2023
NSCLC Trial in Goyang-si (BIBW 2992, simvastatin)
Completed
- Non-small Cell Lung Cancer
- BIBW 2992
- simvastatin
-
Goyang-si, Gyeonggi-do, Korea, Republic ofNational Cancer Center
Apr 4, 2022
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic
Recruiting
- Liver and Intrahepatic Bile Duct Carcinoma
- +5 more
- Dexamethasone
- +6 more
-
Portland, OregonOHSU Knight Cancer Institute
Oct 11, 2022
Endometrial Cancer Trial in Houston (Paclitaxel, Carboplatin, Dostarlimab)
Not yet recruiting
- Endometrial Cancer
- Paclitaxel
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Apr 6, 2023
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic Trial in Scottsdale (Botensilimab, Balstilimab, Chloroquine
Not yet recruiting
- Pancreatic Cancer Metastatic
- Pancreatic Adenocarcinoma Metastatic
- Botensilimab
- +3 more
-
Scottsdale, ArizonaClinical Trials Nurse Navigator
Oct 3, 2023
Heart Failure Trial in Cairo (myocardial function after surgery)
Recruiting
- Heart Failure
- myocardial function after surgery
-
Cairo, Egypt
- +1 more
Oct 13, 2023
Recurrent Non-Small Cell Lung Carcinoma, Stage I NSCLC, Stage II NSCLC Trial in United States (TG4010, Nivolumab)
Completed
- Recurrent Non-Small Cell Lung Carcinoma
- +5 more
- TG4010
- Nivolumab
-
Duarte, California
- +3 more
Oct 11, 2021